FRACTYL HEALTH, INC.
GUTSNasdaq
$0.81
↓ -5.2%Jul 17 close · end-of-day
Price
1Y↓ -50.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$128.4M
Enterprise Value
$65.2M
P/E
—
P/S
—
P/B
6.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$108.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-505.2%
ROIC
—
Debt / Equity
—
Net Cash
$63.2M
Return 1Y
-54.8%
Company profile
We are a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. We were incorporated under the laws of the state of Delaware on August 30, 2010 under the name MedCatalyst, Inc. On January 12, 2012, we changed our name to Fractyl Laboratories Inc. On June 9, 2021, we changed our name to Fractyl Health, Inc. Our principal executive offices are located at 17 Hartwell Avenue, Lexington, Massachusetts.
- CEO
- Harith Rajagopalan
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Headquarters
- Massachusetts
- Website
- www.fractyl.com
Management & directors
- Rajagopalan HarithChief Executive Officer
- Smith Weber LaraChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
GUTS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS$0.06↓ -112.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $120,000.00 | $93,000.00 | $0.00 |
| Gross profit | $43,000.00 | $43,000.00 | — |
| Operating income | -$50.8M | -$93.5M | -$96.8M |
| Net income | -$77.1M | -$68.7M | -$141.0M |
| Diluted EPS | -$45.29 | -$1.62 | -$1.86 |
| Operating cash flow | -$42.8M | -$65.5M | -$90.3M |
| Free cash flow | -$43.2M | -$67.3M | -$90.9M |
| Gross margin | 35.8% | 46.2% | — |
| Operating margin | -42363.3% | -100571.0% | — |
| Net margin | -64242.5% | -73864.5% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $43,000.00 | $14,000.00 | $3,000.00 | — | — | — | — | — |
| Gross profit | $19,000.00 | $7,000.00 | $3,000.00 | — | — | — | — | — |
| Operating income | -$23.0M | -$23.8M | -$25.2M | -$24.8M | -$26.1M | -$22.7M | -$23.3M | -$20.8M |
| Net income | -$17.2M | -$23.2M | -$25.0M | -$23.7M | -$27.9M | -$45.6M | -$43.7M | $9.2M |
| Diluted EPS | -$0.36 | -$0.48 | -$0.61 | -$0.49 | -$0.57 | -$0.71 | -$0.09 | $0.06 |
| Operating cash flow | -$18.7M | -$18.0M | -$17.0M | -$25.1M | -$21.2M | -$22.7M | -$21.3M | -$22.5M |
| Free cash flow | -$19.0M | -$18.3M | -$17.3M | -$25.5M | -$21.3M | -$22.7M | -$21.3M | — |
| Gross margin | 44.2% | 50.0% | 100.0% | — | — | — | — | — |
| Operating margin | -53453.5% | -169957.1% | -840333.3% | — | — | — | — | — |
| Net margin | -40067.4% | -165521.4% | -832333.3% | — | — | — | — | — |
Company news
Jul 16, 2026
Jul 15, 2026
Jul 11, 2026
Jun 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-12 | Royan Ajay | Buy | 23,000 | $0.85 | $19,596.00 | filing |
| 2026-06-10 | BRADLEY WILLIAM | Buy | 68,493 | $0.73 | $50,328.66 | filing |
| 2026-06-10 | Sheffield Ian | Buy | 35,000 | $0.73 | $25,529.00 | filing |
| 2026-06-10 | Rajagopalan Harith· Chief Executive Officer | Buy | 25,000 | $0.73 | $18,252.50 | filing |
| 2026-06-08 | Smith Weber Lara· Chief Financial Officer | Buy | 20,000 | $0.69 | $13,708.00 | filing |
| 2025-12-04 | Rajagopalan Harith· Chief Executive Officer | Buy | 10,416 | $1.92 | $19,998.72 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.